Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Weighing the outcomes

The emergent healthcare value era, its consequences, and what drug firms need to do about it

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Growth in drug expenditures.
Figure 2
Figure 3: Biotech drugs in the oncology pipeline.

References

  1. IMS Health. IMS Health Reports Global Pharmaceutical Market Grew 7.0 Percent in 2006, to $643 Billion (IMS, Norwalk, CT, USA, March 20, 2007). http://www.imshealth.com/ims/portal/front/ articleC/0,2777,6599_3665_80560241,00.html

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

CardioVascular BioTherapeutics is a client of the Bruckner Group.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Russo, M., Balekdjian, D. Weighing the outcomes. Nat Biotechnol 26, 173–182 (2008). https://doi.org/10.1038/nbt0208-173

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0208-173

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing